Clinical Study of S-1 Plus Oxaliplatin Versus S-1 Plus Cisplatin As the First-Line Treatment for Elderly Patients with Advanced Gastric Cancer

Yang Mi

2013-01-01

Chinese Clinical Oncology

Abstract:Objective To investigate the efficacy and toxicity of S-1 plus oxaliplatin versus S-1 plus cisplatin as the first-line treatment for elderly patients with advanced gastric cancer.Methods Fifty-six elderly patients with advanced gastric cancer were randomly divided into S-1 plus oxaliplatin group(SOX,n=30) and S-1 plus cisplatin group(SP,n=26).In SOX group,S-1 was administered orally(40-60mg,bid) from d1 to d14,and oxalipatin(130mg/m2) was administered intravenously on d1.Every 21 days was a cycle.In SP group,cisplatin was administered intravenously 25mg/m2 on d1-d3,and the administration of S-1 followed the same dosage as SOX group.Every 21 days was a cycle.Efficacy was evaluated every two cycles.Results The effective rates of SOX group and SP group were 46.7% and 38.5%(P=0.596),the disease control rates were 80.0% and 76.9%(P=1.000),the median progress-free survival were 6.0 months and 5.6 months(P=0.831),and the median overall survival were 12.3months and 11.5 months(P=0.401).The main toxicity in the two groups was hematological toxicity,and the occurrence of grade 3-4 toxicity in SOX group and SP group had no difference.The non-hematological toxicity in the two groups was all in grade 1-2,and the main toxicity was peripheral neuritis in SOX group,while in SP group were abnormal renal function and nausea/vomitting.The improvement rate of KPS score in SOX group and SP group were 83.3% and 46.2%(P=0.027),and the increased rate of FACT-G score were 76.7% and 38.5%(P=0.006).Conclusion Both SOX and SP regimen are effective for elderly patients with advanced gastric cancer.Compared with SP regimen,SOX regimen is better tolerated as the first-line treatment for advanced gastric cancer.